PL2697227T3 - Skondensowane pochodne imidazolu użyteczne jako inhibitory IDO - Google Patents

Skondensowane pochodne imidazolu użyteczne jako inhibitory IDO

Info

Publication number: PL2697227T3
Authority: PL; Poland
Prior art keywords: imidazole derivatives; derivatives useful; ido inhibitors; fused imidazole; fused
Prior art date: 2011-04-15

Application number

PL12715295.7T

Other languages

English (en)

Inventor

Mario Mautino

Sanjeev Kumar

Jesse Waldo

Firoz Jaipuri

Tanay Kesharwani

Xiaoxia Zhang

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-15

Filing date

2012-04-12

Publication date

2016-09-30

2012-04-12 Application filed filed Critical

2016-09-30 Publication of PL2697227T3 publication Critical patent/PL2697227T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

PL12715295.7T 2011-04-15 2012-04-12 Skondensowane pochodne imidazolu użyteczne jako inhibitory IDO PL2697227T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161475788P	2011-04-15	2011-04-15

Publications (1)

Publication Number	Publication Date
PL2697227T3 true PL2697227T3 (pl)	2016-09-30

Family

ID=45976556

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15197593T PL3018132T3 (pl)	2011-04-15	2012-04-12	Skondensowane pochodne imidazolu użyteczne jako inhibitory ido
PL12715295.7T PL2697227T3 (pl)	2011-04-15	2012-04-12	Skondensowane pochodne imidazolu użyteczne jako inhibitory IDO

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL15197593T PL3018132T3 (pl)	2011-04-15	2012-04-12	Skondensowane pochodne imidazolu użyteczne jako inhibitory ido

Country Status (30)

Country	Link
US (5)	US9260434B2 (pl)
EP (3)	EP3348558A1 (pl)
JP (4)	JP2014511876A (pl)
KR (1)	KR102164443B1 (pl)
CN (2)	CN103547579B (pl)
AU (4)	AU2012242871C1 (pl)
BR (1)	BR112013026494A2 (pl)
CA (1)	CA2833296C (pl)
CL (1)	CL2013002990A1 (pl)
CO (1)	CO6862146A2 (pl)
CY (1)	CY1117440T1 (pl)
DK (2)	DK3018132T3 (pl)
ES (2)	ES2660831T3 (pl)
HK (1)	HK1256355A1 (pl)
HR (2)	HRP20160369T1 (pl)
HU (2)	HUE027316T2 (pl)
IL (3)	IL228862A (pl)
LT (1)	LT3018132T (pl)
ME (1)	ME02417B (pl)
MX (1)	MX340442B (pl)
NO (1)	NO2694640T3 (pl)
NZ (2)	NZ723271A (pl)
PE (2)	PE20141124A1 (pl)
PL (2)	PL3018132T3 (pl)
PT (1)	PT3018132T (pl)
RS (2)	RS56992B1 (pl)
RU (2)	RU2017107026A (pl)
SI (2)	SI3018132T1 (pl)
SM (1)	SMT201600130B (pl)
WO (1)	WO2012142237A1 (pl)

Families Citing this family (275)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO2694640T3 (pl)	2011-04-15	2018-03-17
WO2013009701A2 (en)	2011-07-08	2013-01-17	The University Of North Carolina At Chapel Hill	Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2014159248A1 (en) *	2013-03-14	2014-10-02	Newlink Genetics Corporation	Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US9815811B2 (en)	2013-03-14	2017-11-14	Curadev Pharma, Pvt. Ltd.	Inhibitors of the kynurenine pathway
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
CN103382187B (zh) *	2013-08-06	2015-06-03	信实生物医药（上海）有限公司	一种3-氯-7(5)-溴苯并异恶唑的合成方法
EP3466949B1 (en)	2013-12-24	2020-12-23	Bristol-Myers Squibb Company	Tricyclic compound as anticancer agents
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
RS59643B1 (sr)	2014-06-06	2020-01-31	Bristol Myers Squibb Co	Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
EP3189054B1 (en) *	2014-09-05	2019-07-24	Merck Patent GmbH	(1-fluoro-cyclohex-1-yl)-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) *	2014-10-01	2014-11-12	Redx Pharma Ltd	Compounds
GB201418300D0 (en) *	2014-10-15	2014-11-26	Redx Pharma Ltd	Compounds
BR112017008575B1 (pt)	2014-10-29	2021-07-13	Bicyclerd Limited	Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica
EA202090956A3 (ru)	2014-11-21	2020-12-30	Бристол-Майерс Сквибб Компани	Антитела к cd73 и их применения
WO2016100851A1 (en)	2014-12-18	2016-06-23	Lankenau Institute For Medical Research	Methods and compositions for the treatment of retinopathy and other ocular diseases
AR103232A1 (es)	2014-12-22	2017-04-26	Bristol Myers Squibb Co	ANTAGONISTAS DE TGFbR
CA2971732A1 (en)	2014-12-23	2016-06-30	Bristol-Myers Squibb Company	Antibodies to tigit
US10983128B2 (en)	2015-02-05	2021-04-20	Bristol-Myers Squibb Company	CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN105884828A (zh) *	2015-02-16	2016-08-24	上海迪诺医药科技有限公司	多环化合物、其药物组合物及应用
SG11201705821XA (en)	2015-03-02	2017-08-30	Rigel Pharmaceuticals Inc	TGF-ß INHIBITORS
JP2018519245A (ja)	2015-04-03	2018-07-19	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
TW201642897A (zh)	2015-04-08	2016-12-16	Ｆ星生物科技有限公司	Ｈｅｒ２結合劑治療
TWI698435B (zh) *	2015-04-10	2020-07-11	英屬開曼群島商百濟神州有限公司	作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶
CN108026098B (zh) *	2015-04-12	2019-09-03	杭州英创医药科技有限公司	作为ido和tdo抑制剂的杂环化合物
AU2016249981B2 (en)	2015-04-13	2022-02-17	Five Prime Therapeutics, Inc.	Combination therapy for cancer
CN106715440B (zh) *	2015-04-21	2019-02-22	江苏恒瑞医药股份有限公司	咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
EP3294736B1 (en)	2015-05-11	2020-07-22	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
US9725449B2 (en)	2015-05-12	2017-08-08	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
US10174024B2 (en)	2015-05-12	2019-01-08	Bristol-Myers Squibb Company	5H-pyrido[3,2-B]indole compounds as anticancer agents
EA035412B1 (ru)	2015-05-29	2020-06-10	Бристол-Майерс Сквибб Компани	Антитела к ox40 и их применение
GB2548542A (en) *	2015-06-16	2017-09-27	Redx Pharma Plc	Compounds
CN106256830B (zh) *	2015-06-18	2019-03-08	成都海创药业有限公司	一种氘代的ido抑制剂及其制备方法和用途
AU2016285920A1 (en)	2015-06-29	2018-02-01	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
CN105037371A (zh) *	2015-06-30	2015-11-11	西华大学	一种氘代的吲哚胺-2,3-双加氧酶抑制剂
GB201511790D0 (en)	2015-07-06	2015-08-19	Iomet Pharma Ltd	Pharmaceutical compound
CN115887671A (zh)	2015-07-16	2023-04-04	百欧肯治疗有限公司	治疗癌症的组合物及方法
KR20180086300A (ko)	2015-07-24	2018-07-30	뉴링크 제네틱스 코퍼레이션	1-메틸-d-트립토판의 염 및 프로드러그
KR20180034548A (ko)	2015-07-28	2018-04-04	브리스톨-마이어스 스큅 컴퍼니	Tgf 베타 수용체 길항제
US10772962B2 (en)	2015-08-19	2020-09-15	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP2018525415A (ja)	2015-08-25	2018-09-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｔｇｆベータ受容体アンタゴニスト
CN106478634B (zh) *	2015-09-01	2020-05-22	尚华医药科技(江西)有限公司	稠合咪唑化合物、其制备方法、药物组合物和用途
WO2017075341A1 (en) *	2015-10-29	2017-05-04	Scifluor Life Sciences, Inc.	Fused imidazole derivatives as ido/tdo inhibitors
CR20180306A (es)	2015-11-02	2018-10-16	Five Prime Therapeutics Inc	Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
WO2017080934A1 (en) *	2015-11-09	2017-05-18	F. Hoffmann-La Roche Ag	Screening assay to identify id01 and/or tdo modulators
CA3005855A1 (en)	2015-11-19	2017-05-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3380523A1 (en)	2015-11-23	2018-10-03	Five Prime Therapeutics, Inc.	Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
WO2017106291A1 (en)	2015-12-15	2017-06-22	Bristol-Myers Squibb Company	Cxcr4 receptor antagonists
EP3394068B1 (en) *	2015-12-24	2024-09-11	Genentech, Inc.	Tdo2 inhibitors
CN107056785B (zh) *	2016-01-02	2021-06-22	杭州英创医药科技有限公司	作为ido和tdo抑制剂的杂环化合物
AU2017215424A1 (en)	2016-02-02	2018-08-09	Emcure Pharmaceuticals Limited	Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
JP7066186B2 (ja)	2016-02-19	2022-05-13	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	肥満の処置のための方法及び医薬組成物
JP6892876B2 (ja) *	2016-02-19	2021-06-23	チアタイティエンチンファーマシューティカルグループカンパニーリミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd.	免疫調節剤としての三環式化合物
CN108884104B (zh) *	2016-02-19	2021-01-15	正大天晴药业集团股份有限公司	作为免疫调节剂的三并环化合物
WO2017149469A1 (en)	2016-03-03	2017-09-08	Emcure Pharmaceuticals Limited	Heterocyclic compounds useful as ido and/or tdo modulators
AU2017228470A1 (en)	2016-03-04	2018-08-30	Bristol-Myers Squibb Company	Combination therapy with anti-CD73 antibodies
CN105732643A (zh) *	2016-04-18	2016-07-06	苏州大学	一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
AU2017252527A1 (en)	2016-04-18	2018-11-08	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human CD40 and uses thereof
CN107312005B (zh) *	2016-04-27	2021-12-17	上海翰森生物医药科技有限公司	具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
KR20190003687A (ko)	2016-05-04	2019-01-09	브리스톨-마이어스 스큅 컴퍼니	인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
EP3452450A1 (en)	2016-05-04	2019-03-13	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3452029A4 (en)	2016-05-04	2019-10-30	Bristol-Myers Squibb Company	INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3452452A4 (en)	2016-05-04	2019-10-30	Bristol-Myers Squibb Company	INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
WO2017192813A1 (en)	2016-05-04	2017-11-09	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017197055A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN105902542A (zh) *	2016-05-16	2016-08-31	张阳	一种偶联物在制备治疗心血管疾病药物中的应用
CN107556316B (zh) *	2016-06-30	2021-11-12	鲁南制药集团股份有限公司	含桥环的咪唑衍生物
WO2017198159A1 (zh) *	2016-05-16	2017-11-23	鲁南制药集团股份有限公司	含桥环的咪唑衍生物
CN107383012B (zh) *	2016-05-16	2021-09-28	鲁南制药集团股份有限公司	含二环的咪唑醇衍生物
CN106957318B (zh) *	2016-05-19	2019-12-10	中国科学院上海有机化学研究所	稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
US11246877B2 (en)	2016-05-20	2022-02-15	The University Of Chicago	Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
AR108586A1 (es) *	2016-06-10	2018-09-05	Lilly Co Eli	Compuestos de 2,3-dihidro-1h-indol
CN107488179B (zh) *	2016-06-11	2024-06-07	鲁南制药集团股份有限公司	含桥环的咪唑醇衍生物
CN107556315B (zh) *	2016-06-30	2021-08-31	鲁南制药集团股份有限公司	含四元环的咪唑衍生物
US20190248893A1 (en)	2016-07-14	2019-08-15	Bristol-Myers Squibb Company	Antibodies against tim3 and uses thereof
US20190292179A1 (en)	2016-07-21	2019-09-26	Bristol-Myers Squibb Company	TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) *	2016-07-29	2018-02-06	上海迪诺医药科技有限公司	多环化合物、其药物组合物及应用
CN107698594A (zh) *	2016-08-09	2018-02-16	苏州国匡医药科技有限公司	吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途
EP3503916A1 (en)	2016-08-26	2019-07-03	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018045966A1 (zh) *	2016-09-12	2018-03-15	广州必贝特医药技术有限公司	含咪唑稠合三环类化合物及其应用
TW201815766A (zh)	2016-09-22	2018-05-01	美商普雷辛肯公司	用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CN109952300B (zh)	2016-09-24	2022-01-18	百济神州有限公司	5或8-取代的咪唑并[1,5-a]吡啶
CN110381963A (zh)	2016-10-13	2019-10-25	朱诺治疗学股份有限公司	涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物
WO2018072742A1 (zh) *	2016-10-21	2018-04-26	江苏恒瑞医药股份有限公司	一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
TW201815417A (zh) *	2016-10-21	2018-05-01	蘇州盛迪亞生物醫藥有限公司	Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
US11028064B2 (en)	2016-11-04	2021-06-08	Auckland Uniservices Limited	Tricyclic heterocyclic derivatives and uses thereof
CN106474468B (zh) *	2016-11-23	2020-03-27	中国医学科学院医学生物学研究所	一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
WO2018106579A1 (en) *	2016-12-06	2018-06-14	Albert Einstein College Of Medicine, Inc.	Drug targeting of human indoleamine 2,3-dioxygenase
CN108203438B (zh) *	2016-12-20	2021-09-28	深圳微芯生物科技股份有限公司	具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
ES2881395T3 (es)	2016-12-22	2021-11-29	Calithera Biosciences Inc	Composiciones y métodos para inhibir la actividad de la arginasa
CN108239091B (zh) *	2016-12-26	2021-08-13	中国医学科学院药物研究所	1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
WO2018132279A1 (en)	2017-01-05	2018-07-19	Bristol-Myers Squibb Company	Tgf beta receptor antagonists
US11173145B2 (en)	2017-01-17	2021-11-16	Board Of Regents, The University Of Texas System	Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018175954A1 (en)	2017-03-23	2018-09-27	F. Hoffmann-La Roche Ag	Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
EP3601353A1 (en)	2017-03-31	2020-02-05	Five Prime Therapeutics, Inc.	Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
AU2018256459B2 (en)	2017-04-21	2023-12-07	Ikena Oncology, Inc.	Indole AHR inhibitors and uses thereof
CA3057866A1 (en)	2017-04-28	2018-11-01	Five Prime Therapeutics, Inc.	Methods of treatment with cd80 extracellular domain polypeptides
US11066392B2 (en)	2017-05-12	2021-07-20	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) *	2017-05-31	2019-11-12	成都海博锐药业有限公司	一种ido抑制剂化合物、药用组合物、用途
US11827639B2 (en)	2017-06-28	2023-11-28	Genentech, Inc.	TDO2 and IDO1 inhibitors
EP3645533B1 (en)	2017-06-28	2025-03-26	Genentech, Inc.	Tdo2 and ido1 inhibitors
MX391848B (es)	2017-06-30	2025-03-19	Bristol Myers Squibb Co	Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido)
EP3658565B1 (en)	2017-07-28	2022-11-09	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
CN111194232B (zh)	2017-08-02	2023-01-31	芝加哥大学	纳米级金属有机层和金属有机纳米片
CN118772242A (zh)	2017-08-04	2024-10-15	拜斯科技术开发有限公司	Cd137特异性的双环肽配体
WO2019029507A1 (zh) *	2017-08-08	2019-02-14	江苏恒瑞医药股份有限公司	一种咪唑并异吲哚类衍生物的制备方法
CN109384791B (zh) *	2017-08-09	2020-09-11	江苏恒瑞医药股份有限公司	一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
BR112020003116A2 (pt)	2017-08-17	2020-08-04	Ikena Oncology, Inc.	inibidores de ahr e usos dos mesmos
EP3668880B1 (en)	2017-08-17	2021-10-06	Idorsia Pharmaceuticals Ltd	Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
EP3670518A4 (en) *	2017-08-18	2021-01-06	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TRICYCLIC COMPOUND CRYSTALS
EP3676279B1 (en)	2017-08-31	2021-12-01	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
US10947263B2 (en)	2017-08-31	2021-03-16	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
CN111032672B (zh)	2017-08-31	2024-09-13	百时美施贵宝公司	作为抗癌剂的环二核苷酸
CN107501272B (zh) *	2017-09-05	2020-03-31	中国药科大学	咪唑并异吲哚类ido1抑制剂、其制备方法及应用
WO2019055786A1 (en)	2017-09-14	2019-03-21	Lankenau Institute For Medical Research	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2019060742A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc	AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
WO2019060693A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	CRBN LIGANDS AND USES THEREOF
WO2019074824A1 (en)	2017-10-09	2019-04-18	Bristol-Myers Squibb Company	INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2019074822A1 (en)	2017-10-09	2019-04-18	Bristol-Myers Squibb Company	INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US11230601B2 (en)	2017-10-10	2022-01-25	Tilos Therapeutics, Inc.	Methods of using anti-lap antibodies
KR20200061399A (ko)	2017-10-10	2020-06-02	브리스톨-마이어스 스큅 컴퍼니	항암제로서의 시클릭 디뉴클레오티드
JP7254821B2 (ja)	2017-10-16	2023-04-10	ブリストル－マイヤーズスクイブカンパニー	抗がん剤としての環状ジヌクレオチド
US12209079B2 (en)	2017-10-19	2025-01-28	General Incorporated Association Pharma Valley Project Supporting Organization	IDO/TDO inhibitor
US11603410B2 (en)	2017-11-01	2023-03-14	Bristol-Myers Squibb Company	Immunostimulatory agonistic antibodies for use in treating cancer
CN111527084B (zh)	2017-11-06	2023-07-18	百时美施贵宝公司	可用作hpk1抑制剂的异呋喃酮化合物
CN111386114A (zh)	2017-11-25	2020-07-07	百济神州有限公司	作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
KR102813744B1 (ko)	2017-12-27	2025-05-28	브리스톨-마이어스 스큅 컴퍼니	항-cd40 항체 및 그의 용도
WO2019136112A1 (en)	2018-01-05	2019-07-11	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN111886255B (zh)	2018-01-12	2025-04-04	百时美施贵宝公司	抗tim3抗体及其用途
EP3737666A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP3737675A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
WO2019138107A1 (en)	2018-01-15	2019-07-18	Idorsia Pharmaceuticals Ltd	Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
CN111247119B (zh) *	2018-01-19	2023-02-03	四川科伦博泰生物医药股份有限公司	脒类和胍类衍生物、其制备方法及其在医药上的应用
TWI816742B (zh)	2018-01-29	2023-10-01	美商維泰克斯製藥公司	Gcn2抑制劑及其用途
BR112020015396A2 (pt)	2018-01-29	2020-12-08	Merck Patent Gmbh	Inididores de gcn2 e usos dos mesmos
US10519187B2 (en)	2018-02-13	2019-12-31	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
KR20200130362A (ko)	2018-03-08	2020-11-18	브리스톨-마이어스 스큅 컴퍼니	항암제로서의 시클릭 디뉴클레오티드
US11149011B2 (en)	2018-03-20	2021-10-19	Plexxikon Inc.	Compounds and methods for IDO and TDO modulation, and indications therefor
AU2019239747A1 (en)	2018-03-21	2020-10-08	Bristol-Myers Squibb Company	Antibodies binding to VISTA at acidic pH
WO2019183551A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
MX2020010604A (es)	2018-04-12	2020-10-20	Bristol Myers Squibb Co	Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
CA3096546A1 (en)	2018-04-16	2019-10-24	Arrys Therapeutics, Inc.	Ep4 inhibitors and use thereof
US12037323B2 (en)	2018-05-03	2024-07-16	Bristol-Myers Squibb Company	Uracil derivatives as Mer-AXL inhibitors
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
SMT202300170T1 (it)	2018-06-27	2023-09-06	Bristol Myers Squibb Co	Composti naftiridinonici utili come attivatori dei linfociti t
SG11202012972YA (en)	2018-06-27	2021-01-28	Bristol Myers Squibb Co	Substituted naphthyridinone compounds useful as t cell activators
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
CA3104530A1 (en)	2018-07-09	2020-01-16	Five Prime Therapeutics, Inc.	Antibodies binding to ilt4
CN112638948A (zh)	2018-07-11	2021-04-09	戊瑞治疗有限公司	在酸性pH下结合至VISTA的抗体
WO2020018670A1 (en)	2018-07-17	2020-01-23	Board Of Regents, The University Of Texas System	Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020023356A1 (en)	2018-07-23	2020-01-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en)	2018-07-23	2024-08-13	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en)	2018-08-29	2021-03-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en)	2018-08-29	2022-02-22	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2022500499A (ja)	2018-09-07	2022-01-04	ピクセラピューティクス，インコーポレイテッド	Ｅｉｆ４ｅ阻害剤およびその使用
CN110950842B (zh) *	2018-09-27	2023-06-20	深圳微芯生物科技股份有限公司	具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
TW202035445A (zh)	2018-10-10	2020-10-01	美商帝洛斯療法股份有限公司	抗lap抗體變異體及其用途
BR112021009111A2 (pt)	2018-11-16	2021-08-24	Bristol-Myers Squibb Company	Anticorpos anti-nkg2a e usos dos mesmos
CN113423427A (zh)	2018-11-30	2021-09-21	凯麦拉医疗公司	Irak降解剂和其用途
GB201820288D0 (en)	2018-12-13	2019-01-30	Bicycle Tx Ltd	Bicycle peptide ligaands specific for MT1-MMP
EP3897631A4 (en)	2018-12-20	2022-11-23	C4 Therapeutics, Inc.	TARGETED PROTEIN DEGRADATION
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020187998A1 (en)	2019-03-19	2020-09-24	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
EP3946462A1 (en)	2019-04-02	2022-02-09	BicycleTX Limited	Bicycle toxin conjugates and uses thereof
BR112021019748A2 (pt)	2019-04-05	2021-12-07	Kymera Therapeutics Inc	Degradadores de stat e usos dos mesmos
US12012374B2 (en)	2019-05-13	2024-06-18	Bristol-Myers Squibb Company	Agonists of ROR GAMMAt
US20230295087A1 (en)	2019-05-13	2023-09-21	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
AU2020282759A1 (en)	2019-05-31	2021-12-23	Ikena Oncology, Inc.	TEAD inhibitors and uses thereof
WO2021005222A1 (en)	2019-07-11	2021-01-14	Idorsia Pharmaceuticals Ltd	Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US20220306630A1 (en)	2019-08-06	2022-09-29	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
AR119821A1 (es)	2019-08-28	2022-01-12	Bristol Myers Squibb Co	Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AU2020347274A1 (en)	2019-09-13	2022-03-31	Nimbus Saturn, Inc.	HPK1 antagonists and uses thereof
EP4031575A1 (en)	2019-09-19	2022-07-27	Bristol-Myers Squibb Company	Antibodies binding to vista at acidic ph
AR120481A1 (es)	2019-11-19	2022-02-16	Bristol Myers Squibb Co	Compuestos útiles como inhibidores de la proteína helios
CN115279764A (zh)	2019-11-26	2022-11-01	医肯纳肿瘤学公司	多晶型咔唑衍生物及其用途
MX2022006134A (es)	2019-11-26	2022-06-17	Bristol Myers Squibb Co	Sales/cocristales de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroqu inolin-4-il)ciclohexil)propanamida.
CN111333653A (zh) *	2019-12-16	2020-06-26	山东大学	一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
US11779578B2 (en)	2019-12-17	2023-10-10	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
WO2021127283A2 (en)	2019-12-17	2021-06-24	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
US20230118629A1 (en)	2019-12-23	2023-04-20	Bristol-Myers Squibb Company	Substituted piperazine derivatives useful as t cell activators
IL294269A (en)	2019-12-23	2022-08-01	Bristol Myers Squibb Co	Substituted quinolinonyl piperazine compounds useful as t cell activators
AU2020412780A1 (en)	2019-12-23	2022-07-21	Kymera Therapeutics, Inc.	SMARCA degraders and uses thereof
US20230094758A1 (en)	2019-12-23	2023-03-30	Bristol-Myers Squibb Company	Substituted quinazolinyl compounds useful as t cell activators
IL294273A (en)	2019-12-23	2022-08-01	Bristol Myers Squibb Co	Substituted heteroaryl compounds useful as t cell activators
AR120823A1 (es)	2019-12-23	2022-03-23	Bristol Myers Squibb Co	Compuestos bicíclicos sustituidos útiles como activadores de células t
JP2023517794A (ja)	2020-01-06	2023-04-27	ハイファイバイオ（ホンコン）リミテッド	抗ｔｎｆｒ２抗体及びその使用
MX2022008421A (es)	2020-01-07	2022-09-23	Hifibio Hk Ltd	Anticuerpo anti-galectina-9 y usos del mismo.
AR121047A1 (es)	2020-01-15	2022-04-13	Blueprint Medicines Corp	Inhibidores de map4k1
AU2021230289A1 (en)	2020-03-03	2022-09-29	PIC Therapeutics, Inc.	eIF4E inhibitors and uses thereof
KR20220151189A (ko)	2020-03-09	2022-11-14	브리스톨-마이어스 스큅 컴퍼니	증진된 효능제 활성을 갖는 cd40에 대한 항체
US20240424110A1 (en)	2020-03-19	2024-12-26	Kymera Therapeutics, Inc.	Mdm2 degraders and uses thereof
TW202140441A (zh)	2020-03-23	2021-11-01	美商必治妥美雅史谷比公司	經取代之側氧基異吲哚啉化合物
EP4132971A1 (en)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
WO2021247897A1 (en)	2020-06-03	2021-12-09	Kymera Therapeutics, Inc.	Deuterated irak degraders and uses thereof
CN111803635B (zh) *	2020-06-17	2023-03-14	中国医学科学院基础医学研究所	小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2021258010A1 (en)	2020-06-19	2021-12-23	Gossamer Bio Services, Inc.	Oxime compounds useful as t cell activators
US11839659B2 (en)	2020-07-02	2023-12-12	Northwestern University	Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
JP2023536462A (ja)	2020-07-30	2023-08-25	カイメラセラピューティクス，インコーポレイテッド	変異体リンパ腫を処置する方法
IL300537A (en)	2020-08-10	2023-04-01	Gv20 Therapeutics Llc	Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
CA3186504A1 (en)	2020-08-17	2022-02-24	Stephen J. Blakemore	Bicycle conjugates specific for nectin-4 and uses thereof
US20230416382A1 (en)	2020-10-14	2023-12-28	Five Prime Therapeutics, Inc.	Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120354A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2022133083A1 (en)	2020-12-16	2022-06-23	Gossamer Bio Services, Inc.	Compounds useful as t cell activators
CA3202360A1 (en)	2020-12-30	2022-07-07	Nello Mainolfi	Irak degraders and uses thereof
US20250186539A2 (en)	2021-01-11	2025-06-12	Bicycletx Limited	Methods for treating cancer
KR20230152692A (ko)	2021-02-02	2023-11-03	리미널 바이오사이언시스 리미티드	Gpr84 길항제 및 이의 용도
WO2022167457A1 (en)	2021-02-02	2022-08-11	Liminal Biosciences Limited	Gpr84 antagonists and uses thereof
WO2022169921A1 (en)	2021-02-04	2022-08-11	Bristol-Myers Squibb Company	Benzofuran compounds as sting agonists
MX2023009379A (es)	2021-02-12	2023-10-10	Hoffmann La Roche	Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
WO2022174253A1 (en)	2021-02-12	2022-08-18	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
WO2022174269A1 (en)	2021-02-15	2022-08-18	Kymera Therapeutics, Inc.	Irak4 degraders and uses thereof
CA3207049A1 (en)	2021-02-15	2022-08-18	Jared Gollob	Irak4 degraders and uses thereof
WO2022187856A1 (en)	2021-03-05	2022-09-09	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
US20240091202A1 (en)	2021-03-05	2024-03-21	Universität Basel	Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en)	2021-03-05	2022-09-07	Universität Basel Vizerektorat Forschung	Compositions for the treatment of ebv associated diseases or conditions
WO2022192145A1 (en)	2021-03-08	2022-09-15	Blueprint Medicines Corporation	Map4k1 inhibitors
WO2022197641A1 (en)	2021-03-15	2022-09-22	Rapt Therapeutics, Inc.	1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
JP2024513011A (ja)	2021-03-29	2024-03-21	ニンバスサターン，インコーポレイテッド	Ｈｐｋ１アンタゴニスト及びその使用
US20240376224A1 (en)	2021-04-02	2024-11-14	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
EP4320125A1 (en)	2021-04-05	2024-02-14	Bristol-Myers Squibb Company	Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
IL307343A (en)	2021-04-06	2023-11-01	Bristol Myers Squibb Co	Pyridinyl substituted oxisoisoindoline compounds
CA3214952A1 (en)	2021-04-09	2022-10-13	Silvana Marcel LEIT DE MORADEI	Cbl-b modulators and uses thereof
WO2022221866A1 (en)	2021-04-16	2022-10-20	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
CN117715904A (zh)	2021-05-07	2024-03-15	凯麦拉医疗公司	Cdk2降解剂和其用途
JP2024527608A (ja)	2021-07-14	2024-07-25	ブループリントメディシンズコーポレイション	Ｍａｐ４ｋ１阻害剤としての複素環化合物
AR126453A1 (es)	2021-07-15	2023-10-11	Blueprint Medicines Corp	Inhibidores de map4k1
JP2024532276A (ja)	2021-08-25	2024-09-05	ピクセラピューティクス，インコーポレイテッド	ｅＩＦ４Ｅ阻害剤及びその使用
TW202315621A (zh)	2021-08-25	2023-04-16	美商皮克醫療公司	Ｅｉｆ４ｅ抑制劑及其用途
KR20240110592A (ko)	2021-10-29	2024-07-15	카이메라 쎄라퓨틱스 인코포레이티드	Irak4 분해제 및 이의 합성
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2023122772A1 (en)	2021-12-22	2023-06-29	Gossamer Bio Services, Inc.	Oxime derivatives useful as t cell activators
WO2023122778A1 (en)	2021-12-22	2023-06-29	Gossamer Bio Services, Inc.	Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en)	2021-12-22	2023-06-29	Gossamer Bio Services, Inc.	Oxime derivatives useful as t cell activators
US12091411B2 (en)	2022-01-31	2024-09-17	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
EP4472963A1 (en)	2022-02-01	2024-12-11	Arvinas Operations, Inc.	Dgk targeting compounds and uses thereof
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
WO2023230205A1 (en)	2022-05-25	2023-11-30	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
AU2023317741A1 (en)	2022-08-02	2025-03-13	Liminal Biosciences Limited	Aryl-triazolyl and related gpr84 antagonists and uses thereof
EP4565568A1 (en)	2022-08-02	2025-06-11	Liminal Biosciences Limited	Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
IL318576A (en)	2022-08-02	2025-03-01	Liminal Biosciences Ltd	Pyridoxine-substituted GPR84 antagonists and their uses
WO2024036100A1 (en)	2022-08-08	2024-02-15	Bristol-Myers Squibb Company	Substituted tetrazolyl compounds useful as t cell activators
EP4568963A1 (en)	2022-08-09	2025-06-18	Bristol-Myers Squibb Company	Tertiary amine substituted bicyclic compounds useful as t cell activators
EP4568960A1 (en)	2022-08-11	2025-06-18	F. Hoffmann-La Roche AG	Bicyclic tetrahydroazepine derivatives
AR130169A1 (es)	2022-08-11	2024-11-13	Hoffmann La Roche	Derivados de tetrahidrotiazepina bicíclicos
WO2024033389A1 (en)	2022-08-11	2024-02-15	F. Hoffmann-La Roche Ag	Bicyclic tetrahydrothiazepine derivatives
MA71727A (fr)	2022-08-11	2025-05-30	F. Hoffmann-La Roche Ag	Dérivés bicycliques de tétrahydrothiazépine
AR131141A1 (es)	2022-11-22	2025-02-19	Pic Therapeutics Inc	Inhibidores de eif4e y usos de los mismos
CN116143726B (zh) *	2022-12-02	2024-09-06	广州市联瑞制药有限公司	一种环磷腺苷杂质的制备方法
WO2024137865A1 (en)	2022-12-22	2024-06-27	Gossamer Bio Services, Inc.	Compounds useful as t cell activators
TW202500139A (zh)	2023-05-08	2025-01-01	美商必治妥美雅史谷比公司	經取代之苯基㗁唑酮化合物
TW202509014A (zh)	2023-05-10	2025-03-01	美商纜圖藥品公司	ＧＳＫ３α抑制劑及其使用方法
WO2024249540A1 (en)	2023-05-31	2024-12-05	Bristol-Myers Squibb Company	Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en)	2023-06-07	2024-12-12	Bristol-Myers Squibb Company	Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en)	2023-06-23	2024-12-26	Bristol-Myers Squibb Company	Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en)	2023-08-02	2025-02-06	Arvinas Operations, Inc.	Dgk targeting compounds and uses thereof
WO2025064197A1 (en)	2023-09-02	2025-03-27	Bristol-Myers Squibb Company	Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
WO2025049840A1 (en)	2023-09-02	2025-03-06	Bristol-Myers Squibb Company	Substituted phenyl oxooxazolyl piperidine dione compounds
US20250084056A1 (en)	2023-09-13	2025-03-13	Bristol-Myers Squibb Company	Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025096505A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en)	2023-10-31	2025-05-08	Bristol-Myers Squibb Company	Ubiquitin specific processing protease 1 (usp1) compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0126713B1 (de)	1983-05-18	1989-01-18	Ciba-Geigy Ag	Cyclohexandion-carbonsäurederivate mit herbizider und das Pflanzenwachstum regulierender Wirkung
US5807892A (en)	1994-09-30	1998-09-15	Alcon Laboratories, Inc.	Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
AU1628599A (en)	1997-12-05	1999-06-28	Medical College Of Georgia Research Institute, Inc.	Regulation of t cell-mediated immunity by tryptophan
EP1501918A4 (en)	2002-04-12	2006-03-29	Med College Georgia Res Inst	ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO STRENGTHEN OR DECREASE IMMUNE TOLERANCE
EP1613308A4 (en)	2003-03-27	2008-02-20	Lankenau Inst Medical Res	CANCER TREATMENT METHODS
US7598287B2 (en)	2003-04-01	2009-10-06	Medical College Of Georgia Research Institute, Inc.	Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007520559A (ja)	2004-02-03	2007-07-26	アボット・ラボラトリーズ	治療薬としてのアミノベンゾオキサゾール類
EA026785B1 (ru)	2005-05-10	2017-05-31	Инсайт Холдингс Корпорейшн	Модуляторы индоламин 2,3-диоксигеназы и способы их применения
US7705022B2 (en)	2005-10-27	2010-04-27	Lankenau Institute For Medical Research	IDO inhibitors and methods of use thereof
JP5294874B2 (ja)	2005-12-20	2013-09-18	インサイト・コーポレイション	インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
US8389568B2 (en)	2007-03-16	2013-03-05	Lankenau Institute For Medical Research	IDO inhibitors and methods of use thereof
DE102007020493A1 (de)	2007-04-30	2008-11-06	Grünenthal GmbH	Substituierte Amid-Derivate
EP2227233B1 (en) *	2007-11-30	2013-02-13	Newlink Genetics	Ido inhibitors
EA201001030A1 (ru)	2007-12-19	2011-02-28	Амген Инк.	Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
JP2011518841A (ja) *	2008-04-24	2011-06-30	ニューリンクジェネティクス，インコーポレイテッド	Ｉｄｏ阻害剤
SG10201805844QA (en)	2008-07-08	2018-08-30	Incyte Holdings Corp	1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EP2493862B1 (en)	2009-10-28	2016-10-05	Newlink Genetics Corporation	Imidazole derivatives as ido inhibitors
NO2694640T3 (pl) *	2011-04-15	2018-03-17
MX2015006156A (es)	2012-11-20	2015-08-05	Vertex Pharma	Compuestos utiles como inhibidores de endolamina 2,3-dioxigenasa.
WO2014159248A1 (en)	2013-03-14	2014-10-02	Newlink Genetics Corporation	Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US9815811B2 (en)	2013-03-14	2017-11-14	Curadev Pharma, Pvt. Ltd.	Inhibitors of the kynurenine pathway
WO2014141110A2 (en)	2013-03-14	2014-09-18	Curadev Pharma Pvt. Ltd.	Aminonitriles as kynurenine pathway inhibitors
BR112015021999A8 (pt)	2013-03-15	2019-12-03	Bristol Myers Squibb Co	inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
EP2970114B1 (en)	2013-03-15	2019-05-15	Bristol-Myers Squibb Company	Ido inhibitors
US9765018B2 (en)	2013-07-01	2017-09-19	Bristol-Myers Squibb Company	IDO inhibitors
EP3019488B1 (en)	2013-07-11	2018-11-07	Bristol-Myers Squibb Company	Ido inhibitors

2012
- 2012-04-05 NO NO12767723A patent/NO2694640T3/no unknown
- 2012-04-12 WO PCT/US2012/033245 patent/WO2012142237A1/en active Application Filing
- 2012-04-12 RU RU2017107026A patent/RU2017107026A/ru unknown
- 2012-04-12 PE PE2013002332A patent/PE20141124A1/es active IP Right Grant
- 2012-04-12 PL PL15197593T patent/PL3018132T3/pl unknown
- 2012-04-12 CA CA2833296A patent/CA2833296C/en active Active
- 2012-04-12 KR KR1020137030438A patent/KR102164443B1/ko active Active
- 2012-04-12 ES ES15197593.5T patent/ES2660831T3/es active Active
- 2012-04-12 HR HRP20160369TT patent/HRP20160369T1/hr unknown
- 2012-04-12 EP EP17205515.4A patent/EP3348558A1/en not_active Withdrawn
- 2012-04-12 SI SI201231193T patent/SI3018132T1/en unknown
- 2012-04-12 LT LTEP15197593.5T patent/LT3018132T/lt unknown
- 2012-04-12 RS RS20180223A patent/RS56992B1/sr unknown
- 2012-04-12 ME MEP-2016-82A patent/ME02417B/me unknown
- 2012-04-12 PT PT151975935T patent/PT3018132T/pt unknown
- 2012-04-12 DK DK15197593.5T patent/DK3018132T3/en active
- 2012-04-12 RS RS20160285A patent/RS54723B1/en unknown
- 2012-04-12 NZ NZ723271A patent/NZ723271A/en unknown
- 2012-04-12 CN CN201280018684.7A patent/CN103547579B/zh active Active
- 2012-04-12 BR BR112013026494A patent/BR112013026494A2/pt not_active Application Discontinuation
- 2012-04-12 NZ NZ708090A patent/NZ708090A/en unknown
- 2012-04-12 ES ES12715295.7T patent/ES2569665T3/es active Active
- 2012-04-12 JP JP2014505274A patent/JP2014511876A/ja not_active Withdrawn
- 2012-04-12 SI SI201230515A patent/SI2697227T1/sl unknown
- 2012-04-12 HU HUE12715295A patent/HUE027316T2/en unknown
- 2012-04-12 HU HUE15197593A patent/HUE038586T2/hu unknown
- 2012-04-12 EP EP12715295.7A patent/EP2697227B1/en active Active
- 2012-04-12 RU RU2013150811A patent/RU2613579C2/ru active
- 2012-04-12 AU AU2012242871A patent/AU2012242871C1/en active Active
- 2012-04-12 DK DK12715295.7T patent/DK2697227T3/en active
- 2012-04-12 PL PL12715295.7T patent/PL2697227T3/pl unknown
- 2012-04-12 MX MX2013012021A patent/MX340442B/es active IP Right Grant
- 2012-04-12 PE PE2017002751A patent/PE20181023A1/es not_active Application Discontinuation
- 2012-04-12 EP EP15197593.5A patent/EP3018132B1/en active Active
- 2012-04-12 CN CN201510262906.5A patent/CN105111210B/zh active Active
2013
- 2013-10-14 US US14/053,440 patent/US9260434B2/en active Active
- 2013-10-14 IL IL228862A patent/IL228862A/en active IP Right Grant
- 2013-10-15 CL CL2013002990A patent/CL2013002990A1/es unknown
- 2013-11-14 CO CO13268287A patent/CO6862146A2/es active IP Right Grant
2014
- 2014-12-10 AU AU2014274564A patent/AU2014274564B2/en active Active
- 2014-12-22 JP JP2014258630A patent/JP5837673B2/ja active Active
2015
- 2015-07-08 US US14/794,193 patent/US9388191B2/en active Active
- 2015-09-24 IL IL241846A patent/IL241846A/en active IP Right Grant
- 2015-11-05 JP JP2015217361A patent/JP6145491B2/ja active Active
2016
- 2016-04-27 CY CY20161100355T patent/CY1117440T1/el unknown
- 2016-05-04 SM SM201600130T patent/SMT201600130B/it unknown
- 2016-06-13 US US15/181,062 patent/US9850248B2/en active Active
- 2016-06-28 IL IL246515A patent/IL246515B/en active IP Right Grant
- 2016-12-20 AU AU2016277574A patent/AU2016277574B2/en active Active
2017
- 2017-05-15 JP JP2017096307A patent/JP2017149769A/ja not_active Withdrawn
- 2017-11-01 US US15/800,190 patent/US10233190B2/en active Active
2018
- 2018-02-26 HR HRP20180335TT patent/HRP20180335T1/hr unknown
- 2018-04-18 AU AU2018202706A patent/AU2018202706A1/en not_active Abandoned
- 2018-12-03 HK HK18115442.2A patent/HK1256355A1/en unknown
2019
- 2019-02-07 US US16/269,681 patent/US20190225618A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1117440T1 (el)	2017-04-26
SMT201600130B (it)	2016-07-01
NZ723271A (en)	2018-03-23
HRP20160369T1 (hr)	2016-06-03
JP2015061877A (ja)	2015-04-02
PL3018132T3 (pl)	2018-05-30
IL241846A0 (en)	2015-11-30
AU2014274564A1 (en)	2015-01-22
RS54723B1 (en)	2016-08-31
CN105111210A (zh)	2015-12-02
IL228862A (en)	2015-10-29
AU2012242871B2 (en)	2014-09-11
US9260434B2 (en)	2016-02-16
PT3018132T (pt)	2018-03-09
IL228862A0 (en)	2013-12-31
RS56992B1 (sr)	2018-05-31
NZ616457A (en)	2015-05-29
MX2013012021A (es)	2014-07-10
ES2569665T3 (es)	2016-05-12
PE20181023A1 (es)	2018-06-27
US20180118753A1 (en)	2018-05-03
CN103547579A (zh)	2014-01-29
RU2613579C2 (ru)	2017-03-17
EP2697227A1 (en)	2014-02-19
AU2016277574B2 (en)	2018-04-19
US10233190B2 (en)	2019-03-19
ES2660831T3 (es)	2018-03-26
EP3018132B1 (en)	2017-12-13
IL246515B (en)	2018-08-30
BR112013026494A2 (pt)	2016-12-27
JP6145491B2 (ja)	2017-06-14
US20160002249A1 (en)	2016-01-07
NO2694640T3 (pl)	2018-03-17
HRP20180335T1 (hr)	2018-04-20
KR20140059167A (ko)	2014-05-15
HUE038586T2 (hu)	2018-10-29
HK1193822A1 (zh)	2014-10-03
US9388191B2 (en)	2016-07-12
HK1223371A1 (en)	2017-07-28
JP2014511876A (ja)	2014-05-19
HK1256355A1 (en)	2019-09-20
WO2012142237A1 (en)	2012-10-18
AU2014274564B2 (en)	2016-10-06
EP3348558A1 (en)	2018-07-18
DK2697227T3 (en)	2016-04-25
DK3018132T3 (en)	2018-03-12
JP2016029092A (ja)	2016-03-03
AU2012242871A1 (en)	2013-10-31
CL2013002990A1 (es)	2014-07-04
ME02417B (me)	2016-09-20
AU2018202706A1 (en)	2018-05-10
US20160362412A1 (en)	2016-12-15
US9850248B2 (en)	2017-12-26
AU2012242871C1 (en)	2017-02-02
IL241846A (en)	2016-06-30
SI2697227T1 (sl)	2016-06-30
AU2012242871A8 (en)	2013-11-21
CA2833296C (en)	2020-12-08
RU2017107026A (ru)	2019-01-23
MX340442B (es)	2016-07-08
US20190225618A1 (en)	2019-07-25
CN105111210B (zh)	2018-10-09
AU2016277574A1 (en)	2017-01-12
CO6862146A2 (es)	2014-02-10
JP2017149769A (ja)	2017-08-31
RU2013150811A (ru)	2015-05-20
JP5837673B2 (ja)	2015-12-24
CN103547579B (zh)	2017-02-15
WO2012142237A8 (en)	2012-11-22
RU2017107026A3 (pl)	2019-01-23
NZ708090A (en)	2016-12-23
KR102164443B1 (ko)	2020-10-12
PE20141124A1 (es)	2014-09-06
EP3018132A1 (en)	2016-05-11
SI3018132T1 (en)	2018-04-30
LT3018132T (lt)	2018-03-26
US20140066625A1 (en)	2014-03-06
CA2833296A1 (en)	2012-10-18
EP2697227B1 (en)	2016-02-03
HUE027316T2 (en)	2016-10-28

Publication	Publication Date	Title
IL246515B (en)	2018-08-30	Imidazole derivatives are designed for use as ido inhibitors
ZA201303801B (en)	2014-07-30	Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201305612B (en)	2014-05-28	Pyrrolotriazinone derivatives as pi3k inhibitors
IL233366A0 (en)	2014-08-31	Tetra or penta pyridophthalazinones are conjugated as parp inhibitors
SG10201601802YA (en)	2016-04-28	Dispiropyrrolidine derivatives
IL227252A0 (en)	2013-09-30	Aminodihydrothiazine history from sisterhood
IL258704B (en)	2019-05-30	History of hydantoins used as kv3 inhibitors
ZA201305826B (en)	2014-04-30	Substituted amminobutyric derivatives as neprilysin inhibitors
IL228949A0 (en)	2013-12-31	History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
AP3529A (en)	2016-01-11	Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL233365A0 (en)	2014-08-31	Tetra or pentacyclic dihydrodiazepinocarbazolones are conjugated as parp inhibitors
IL247638B (en)	2018-05-31	History of heteroaryl piperidine
IL229990A0 (en)	2014-03-06	History of n-oxypyrazolo-triazapine-dione
EP2744788A4 (en)	2015-04-15	BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
EP2703403A4 (en)	2015-02-11	imidazole
SI2766342T1 (sl)	2016-09-30	Derivati fenil-gvanidina
PL2721009T3 (pl)	2016-01-29	Pochodne pirazolu użyteczne jako inhibitory syntazy aldosteronu
ZA201308049B (en)	2016-08-31	3-ureidoisoquinolin-8-yl derivatives
HK1186463A (en)	2014-03-14	Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201209319B (en)	2013-08-28	Cyclopropyl-indole derivatives
ZA201308697B (en)	2015-01-28	Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en)	2012-01-11	Inhibitors
GB201100183D0 (en)	2011-02-23	Fused aminodihydropyrimidone derivatives